Peptide Association
Start Your Consultation
Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Updated today at 6:00 PM UTC

Clinical TrialsHigh

Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near

The amylin receptor agonist class is emerging as a critical frontier in obesity pharmacology, with drug design decisions increasingly separating competitors in the space. Novo Nordisk's CagriSema, combining an amylin analog with a GLP-1 agonist, is anticipated to become the first approved therapy of its kind later in 2026, while Eli Lilly's mid-stage data are expected to further clarify whether molecular architecture drives meaningful clinical differentiation. The outcome of this design debate carries significant implications for next-generation weight loss pipelines beyond current GLP-1 monotherapy standards.

CagriSemaGLP-1CagrilintideSemaglutide
Endpoints NewsAugust 19, 2026
5 min read
Clinical TrialsHigh

GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause

Experts have raised concerns that GLP-1 receptor agonists may reduce the effectiveness of oral contraceptives, adding a new consideration for clinicians prescribing these widely used therapies. Separately, a phase III trial of avexitide, a first-in-class GLP-1 receptor antagonist, met its primary endpoint, and legal proceedings involving retatrutide have drawn attention to the competitive and regulatory landscape surrounding next-generation weight loss compounds. These developments collectively underscore the rapidly evolving clinical and legal environment surrounding GLP-1 class therapies.

GLP-1AvexitideRetatrutide
MedPage TodayAugust 18, 2026
5 min read
RegulatoryCritical

Watchdog Urges HHS to Investigate Conflicts Among FDA's Peptide Panelists

A consumer watchdog group has formally requested that the HHS Office of Inspector General investigate potential conflicts of interest among members of an FDA advisory committee that recommended adding six peptides to the agency's list of restricted compounds. The demand raises significant questions about the integrity of the advisory process that directly shapes which peptides remain accessible through compounding pharmacies. The outcome of this inquiry could have substantial regulatory implications for providers and patients who rely on compounded peptide therapies.

MedPage TodayAugust 18, 2026
4 min read
IndustryHigh

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

Eli Lilly, a dominant force in the GLP-1 therapeutics market, has entered a collaboration and licensing agreement with OmniAb valued at up to $370 million, targeting ion channel biology. The deal reflects continued aggressive investment by major GLP-1 developers to expand their discovery pipelines and platform capabilities. The partnership signals sustained industry momentum around next-generation approaches that complement or extend existing GLP-1 franchises.

GLP-1Tirzepatide
Endpoints NewsAugust 17, 2026
4 min read
Clinical TrialsHigh

STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

Colorado biotech Enveda has released preliminary Phase 1 data on a novel compound intended to help patients sustain weight loss and preserve muscle mass following GLP-1 receptor agonist therapy. The drug targets pathways associated with exercise adaptation, addressing a key clinical concern around muscle loss that accompanies GLP-1 driven weight reduction. If validated in larger trials, such an agent could become an important adjunct therapy within the expanding GLP-1 treatment landscape.

GLP-1leptin
STAT NewsAugust 18, 2026
5 min read
Clinical TrialsHigh

Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia

Amylyx Pharmaceuticals has announced a successful Phase 3 trial for avexitide, a GLP-1 receptor antagonist targeting post-bariatric hypoglycemia, marking a significant pivot for the company following its prior ALS research program. The positive readout positions avexitide as a potential first-in-class treatment for a condition that affects a meaningful subset of patients who have undergone bariatric surgery. This result underscores the growing therapeutic breadth of GLP-1 pathway modulation beyond weight loss and diabetes management.

avexitideGLP-1
Endpoints NewsAugust 18, 2026
4 min read
BreakthroughHigh

Scientists solve the mystery of a brain "switch" that can trigger weight loss in opposite ways

New research has revealed that the GIP receptor can promote weight loss through two distinct and seemingly contradictory mechanisms depending on its location in the brain. Activating the receptor in the brainstem suppresses appetite, while blocking it in the hypothalamus removes an inhibitory brake on satiety signaling. The findings suggest that combining GIP-targeting therapies with GLP-1 receptor agonists such as semaglutide could yield meaningfully stronger outcomes in obesity treatment.

GLP-1GIPSemaglutideTirzepatide
ScienceDaily Sports MedAugust 15, 2026
4 min read
Clinical TrialsHigh

Preoperative GLP-1s Don't Diminish Bariatric Surgery Results, Study Suggests

A retrospective review of 383 bariatric surgery patients found that preoperative use of GLP-1 receptor agonists did not reduce one-year weight loss outcomes compared to patients with no prior GLP-1 exposure. The findings carry meaningful implications for clinical protocols governing the sequencing of pharmacological and surgical obesity interventions. As GLP-1 medications continue to gain widespread adoption, understanding their interaction with bariatric procedures becomes increasingly important for both prescribers and surgical teams.

GLP-1SemaglutideTirzepatide
MedPage TodayAugust 13, 2026
4 min read
IndustryHigh

STAT+: Eli Lilly targets booming black market for retatrutide

Eli Lilly is taking aim at an expanding black market for retatrutide, a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors that remains under clinical investigation. The emergence of illicit channels for an unapproved compound raises significant concerns around patient safety, product quality, and intellectual property enforcement. The development underscores the widening gap between consumer demand for next-generation metabolic peptide therapies and the pace of regulatory approval.

RetatrutideGLP-1GIP
STAT NewsAugust 13, 2026
4 min read
IndustryHigh

STAT+: Pharmalittle: We're reading about Lilly 'black market' lawsuits, pushback over Trump vaccine plan, and more

Eli Lilly has filed six lawsuits against U.S. companies accused of illegally selling unauthorized versions of its experimental obesity drug retatrutide, a triple agonist peptide in late-stage development. The legal action underscores growing enforcement pressure around compounded and counterfeit versions of GLP-1 class therapies as major pharmaceutical manufacturers move to protect their pipelines. This development is significant for the compounding pharmacy and peptide therapy sectors, which have faced increasing scrutiny over the production and sale of unapproved analogues.

RetatrutideGLP-1
STAT NewsAugust 12, 2026
4 min read
IndustryHigh

GLP-1 Telehealth Platforms Rated by U.S. News

U.S. News and World Report has published its first-ever ratings of telehealth platforms offering GLP-1 weight-loss medications, evaluating 20 online providers dispensing FDA-approved brand-name therapies. The inaugural rankings introduce a new layer of consumer-facing accountability for a rapidly expanding digital prescribing market. The development reflects increasing scrutiny of how GLP-1 drugs are being accessed and distributed outside traditional clinical settings.

GLP-1SemaglutideTirzepatide
MedPage TodayAugust 12, 2026
3 min read
RegulatoryCritical

Eli Lilly files first lawsuits over retatrutide 'black market'

Eli Lilly has initiated legal action against six U.S. companies accused of illegally selling unauthorized versions of retatrutide, the company's investigational GIP, GLP-1, and glucagon receptor triple agonist still in clinical trials. The lawsuits mark the first enforcement litigation by Lilly targeting the illicit compounding and distribution of this pipeline obesity and diabetes drug. The case highlights growing pharmaceutical industry efforts to combat unauthorized peptide sales ahead of potential FDA approval.

RetatrutideGLP-1GIP
Endpoints NewsAugust 12, 2026
4 min read
ResearchHigh

Child Dies in Gene-Editing Trial; Wegovy & Dementia Score; RFK Jr. Questions Journal

New findings indicate that semaglutide, marketed as Wegovy, attenuated a proteomics-based dementia risk score, suggesting potential neuroprotective benefits beyond its established metabolic effects. This adds to a growing body of evidence that GLP-1 receptor agonists may have broad systemic applications beyond weight management and glycemic control. Researchers and clinicians are paying close attention as the therapeutic scope of semaglutide continues to expand across disease indications.

SemaglutideGLP-1
MedPage TodayAugust 11, 2026
4 min read
IndustryHigh

Deaths After GLP-1s; First Detransition Clinic for Youths; DXA Scans Decline

UK government regulators have reported more than 150 deaths possibly linked to injectable GLP-1 weight-loss medications, raising significant safety scrutiny around this class of drugs. The report underscores growing pharmacovigilance concerns as GLP-1 receptor agonists continue to see widespread adoption for obesity and metabolic conditions. Clinicians and regulators are being urged to monitor adverse event data closely as the safety profile of these agents is further evaluated.

GLP-1
MedPage TodayAugust 11, 2026
4 min read
IndustryMedium

Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs

A STAT News opinion piece argues that Medicare's newly launched weight loss drug program introduces access barriers at a critical moment when GLP-1 coverage expansion is gaining momentum. The author contends that program requirements may discourage primary care participation and ultimately limit patient uptake of affordable GLP-1 therapies priced as low as fifty dollars per month. The commentary adds to a broader policy debate about how coverage structures shape real-world access to GLP-1 receptor agonists.

GLP-1Semaglutide
STAT NewsAugust 11, 2026
4 min read
ResearchHigh

PEG Lipids and Cell Penetrating Peptides Improve Delivery and Uptake of Mitochondria

Researchers have demonstrated that PEG lipids and cell-penetrating peptides, tools adapted from lipid nanoparticle and gene therapy platforms, can meaningfully improve the delivery and cellular uptake of transplanted mitochondria. The findings are significant for the field of mitochondrial transplantation therapy, as enhanced uptake efficiency reduces the manufacturing burden associated with producing the large quantities of mitochondria required for human-scale treatment. This work positions cell-penetrating peptides as a functional delivery mechanism in emerging regenerative and longevity medicine applications.

Fight AgingAugust 11, 2026
5 min read
IndustryHigh

Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says

Hims and Hers Health has publicly signaled its readiness to rapidly deploy six consumer wellness peptides currently restricted from compounding pharmacy production, pending potential FDA regulatory relief. The company's CEO made the remarks during second-quarter earnings, underscoring the significant commercial interest building around peptide accessibility through telehealth and compounding channels. This development reflects the intensifying industry focus on FDA policy decisions that could reshape the compounded peptide market.

BPC-157TB-500
Endpoints NewsAugust 11, 2026
4 min read
ResearchHigh

Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects

MedPage Today examines the growing body of attention surrounding side effects associated with GLP-1 receptor agonists, including phenomena colloquially termed "Ozempic teeth" and concerns about muscle loss during rapid weight reduction. The piece highlights how these adverse effect profiles are shaping public perception and clinical conversations around long-term GLP-1 use. Understanding these trade-offs remains central to responsible prescribing and patient counseling in the GLP-1 era.

GLP-1Semaglutide
MedPage TodayAugust 11, 2026
5 min read
LongevityMedium

The Truth About Peptides, NAD, Fasting, & Other Health Trends

A MindBodyGreen podcast episode examines the evidence behind popular health interventions including peptide therapy, NAD supplementation, and intermittent fasting. Researcher Rachele Pojednic offers a science-based assessment of what current data supports versus what remains speculative in the wellness space. The discussion provides a useful framework for clinicians and patients navigating an increasingly crowded landscape of longevity-focused treatments.

MindBodyGreenAugust 9, 2026
4 min read
IndustryMedium

Trans federal employees sue over revoked health coverage

A STAT News morning health digest references expanded access to retatrutide among its bundled news items, signaling continued movement around the investigational GLP-1, GIP, and glucagon triple agonist peptide. The retatrutide mention represents one of several unrelated health stories compiled in the roundup format. Providers and researchers following retatrutide's development pathway may note the access expansion as a marker of its advancing clinical profile.

RetatrutideGLP-1GIP
STAT NewsAugust 4, 2026
3 min read
IndustryMedium

Is 'Gym Penis' Real? Retatrutide Access Expanded; Vitamin D Fails Cancer Test

A MedPage Today daily digest includes a notable item on expanded patient access to retatrutide, Eli Lilly's investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways. Retatrutide has attracted significant clinical interest for its potential to produce greater weight loss than existing approved agents. The digest format covers several unrelated health topics alongside this development.

RetatrutideGLP-1GIP
MedPage TodayAugust 4, 2026
3 min read
ResearchHigh

New Study Shows Which GLP-1s Ranked The Highest For Metabolic Health

A new comparative study evaluates GLP-1 receptor agonists across metabolic and cardiovascular health outcomes, finding meaningful differences between agents beyond their shared weight loss effects. Researchers suggest that the choice of specific GLP-1 therapy may carry distinct implications for heart health independent of body weight reduction. The findings add to a growing body of evidence supporting differentiated clinical decision-making within the GLP-1 drug class.

GLP-1SemaglutideTirzepatide
MindBodyGreenAugust 5, 2026
4 min read
IndustryHigh

Lilly once again beats expectations as tirzepatide accounts for 64% of revenue

Eli Lilly reported $23 billion in second-quarter revenues, surpassing analyst estimates by approximately $3 billion, with tirzepatide driving nearly two-thirds of total sales. The company raised its full-year revenue guidance to between $85 billion and $87 billion, underscoring the dominant commercial trajectory of its dual GIP and GLP-1 receptor agonist. The results reinforce tirzepatide's position as one of the most commercially successful peptide-based therapeutics in pharmaceutical history.

TirzepatideGLP-1GIP
Endpoints NewsAugust 5, 2026
4 min read
IndustryHigh

STAT+: Three biotechs with three news updates

Eli Lilly announced plans to expand access to retatrutide, its investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, marking a notable commercial and clinical development milestone. The move signals growing confidence in retatrutide's trajectory toward broader use ahead of anticipated regulatory submissions. The update is part of a broader biotech news digest that also covers unrelated pharmaceutical litigation.

RetatrutideGLP-1GIP
STAT NewsAugust 4, 2026
3 min read
IndustryHigh

ADA Reviewing Police Tussle; Obesity Trial Lawsuit; Retatrutide's Early Access

Eli Lilly has moved to expand early access to retatrutide, its triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, representing a significant development in the competitive obesity and metabolic disease treatment landscape. The digest also covers ongoing controversies within the American Diabetes Association and litigation tied to obesity clinical trials. Retatrutide has drawn considerable attention for its outsized weight loss outcomes in Phase 2 data.

RetatrutideGLP-1
MedPage TodayAugust 4, 2026
4 min read
Clinical TrialsHigh

Pancreatic Cancer Vaccine Shows Interception Promise in High-Risk Patients

A peptide vaccine targeting KRAS mutations demonstrated preliminary clinical activity in a small study of high-risk pancreatic cancer patients, eliciting KRAS-specific T-cell responses in 18 of 20 participants. The findings represent an early but notable step toward cancer interception using peptide-based immunotherapy. Researchers view the T-cell response rates as encouraging evidence that the vaccine may meaningfully engage the immune system against a historically difficult-to-treat malignancy.

KRAS peptide vaccine
MedPage TodayAugust 4, 2026
4 min read
Clinical TrialsMedium

Millions Eligible For GLP-1s Share The Same Nutrition Blind Spot

A growing body of evidence suggests that patients eligible for GLP-1 receptor agonist therapy share a common nutritional deficiency that may undermine treatment outcomes. The article highlights the importance of integrating targeted dietary interventions alongside pharmacological GLP-1 therapy for optimal results. Clinicians and prescribers working with GLP-1 patients are encouraged to assess and address this nutritional gap as part of a comprehensive care protocol.

GLP-1
MindBodyGreenAugust 4, 2026
4 min read
IndustryHigh

STAT+: Pharmalittle: We're reading about a Lilly access program, a Gilead court victory, and more

Eli Lilly has confirmed an expansion of its early access program for retatrutide, an unapproved triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways for obesity treatment. The move allows a broader patient population to apply before the drug receives regulatory approval, signaling growing confidence in the compound's clinical profile. This development marks a significant step in pre-approval access strategy for next-generation obesity peptide therapeutics.

RetatrutideGLP-1GIP
STAT NewsAugust 4, 2026
3 min read
IndustryMedium

Outbreak Deaths Near 1,600; GLP-1 Temporal Hollowing; Hospitals Get Pay Bump

A MedPage Today digest covers multiple clinical topics, including an observation that GLP-1 receptor agonist use may be associated with temporal hollowing, a facial volume loss effect drawing increasing attention from clinicians managing patients on these therapies. The report contributes to a growing body of anecdotal and clinical observations regarding the aesthetic and physiological side effects of long-term GLP-1 therapy. Providers prescribing GLP-1 agents are advised to monitor patients for this emerging phenomenon as real-world use continues to expand.

GLP-1
MedPage TodayAugust 3, 2026
3 min read
ResearchHigh

Your brain may be wired to regain lost weight

New research highlights the neurological basis of weight regain, explaining how the brain encodes a higher body weight as a biological set point and actively resists subsequent loss through intensified hunger signals and reduced energy expenditure. This mechanism helps clarify the chronic nature of obesity and the clinical rationale for sustained pharmacological intervention. GLP-1 receptor agonists such as semaglutide and tirzepatide are noted for their capacity to modulate these appetite pathways, though the research underscores that efficacy may diminish upon discontinuation of treatment.

SemaglutideTirzepatideGLP-1
ScienceDaily Sports MedAugust 4, 2026
4 min read
ResearchHigh

GLP-1s Beyond Weight Loss — An MD's Guide To The Latest Research

A physician-authored review in MindBodyGreen surveys the expanding body of research on GLP-1 receptor agonists applied to conditions beyond obesity, including cardiovascular health, neurological function, and metabolic disease. The piece synthesizes recent clinical findings to offer practitioners and informed patients a consolidated picture of the broader therapeutic potential of this drug class. As evidence accumulates, GLP-1 agonists are increasingly being evaluated as systemic metabolic modulators rather than purely weight loss agents.

GLP-1SemaglutideTirzepatideLiraglutide
MindBodyGreenAugust 3, 2026
6 min read
Clinical TrialsMedium

Bariatric Surgery Remains an Important Option for Obesity, Despite GLP-1 Drug Boom

As GLP-1 receptor agonists continue to reshape obesity treatment, MedPage Today examines the clinical case for bariatric surgery as a complementary rather than competing intervention. Physicians are navigating patient preferences shifting toward pharmacotherapy while data continue to support durable outcomes from surgical approaches in certain populations. The analysis offers a balanced perspective on how providers can integrate both modalities within evidence-based obesity care.

GLP-1SemaglutideTirzepatide
MedPage TodayAugust 3, 2026
5 min read
RegulatoryCritical

What would it take to get peptides on the shelf?

An FDA advisory panel's recent vote to green-light select popular peptides has drawn significant attention to the consumer peptide market and raised substantive questions about regulatory pathways for these compounds. The NPR report examines what formal FDA oversight would mean for product safety, supply chain integrity, and access for patients currently relying on compounding pharmacies or unregulated sources. The decision marks a potentially pivotal moment in how peptide therapies are classified, distributed, and monitored in the United States.

BPC-157TB-500
NPR HealthAugust 3, 2026
6 min read
IndustryHigh

STAT+: After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers

Eli Lilly's decision to grant a single patient early compassionate access to retatrutide, its investigational triple agonist obesity drug, has prompted widespread questions from physicians seeking the same pathway for their own patients. The case highlights the tension between expanded access protocols and equitable availability of promising pipeline therapies. Industry observers say the episode underscores the need for clearer manufacturer policies as retatrutide advances toward potential approval.

RetatrutideGLP-1GIP
STAT NewsAugust 3, 2026
5 min read
Clinical TrialsMedium

NFL Pro Bowler Has Parkinson's; RFK Jr.'s Cooking Show; GLP-1s and Pregnancy

A MedPage Today news roundup includes a segment on GLP-1 receptor agonist use during pregnancy, a topic of increasing clinical relevance as prescribing rates for this drug class continue to rise. The segment addresses emerging questions around fetal safety and gestational outcomes in patients taking GLP-1 based therapies. Providers managing patients of reproductive age on these agents will find the pregnancy-related discussion pertinent to informed consent and treatment planning.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 31, 2026
4 min read
ResearchMedium

What Does the 'Barbie Peptide' Claim to Offer?

MedPage Today examines the so-called 'Barbie Peptide,' a term that has gained traction in popular and clinical discussions around appearance-enhancing peptide therapies. The quiz format engages clinicians on the purported mechanisms and marketing claims associated with this compound. The piece highlights the growing need for provider education on peptide nomenclature and evidence evaluation.

Melanotan II
MedPage TodayJuly 31, 2026
3 min read
ResearchMedium

The Conservative View on the Current Peptide Craze

Fight Aging offers a measured scientific overview of the peptide therapy landscape, clarifying that only a small subset of the body's peptides are viable therapeutic candidates due to bioavailability and stability constraints. The piece contextualizes the current clinical interest in cell-signaling peptides within the broader universe of peptide biology, helping readers distinguish evidence-based applications from broader enthusiasm. It serves as a useful primer for researchers and clinicians seeking a grounded perspective on peptide therapy's realistic scope.

Fight AgingJuly 29, 2026
5 min read
RegulatoryHigh

The Double Standard in the Peptide Vote

A MedPage Today opinion piece challenges the recent federal advisory committee recommendation on peptides, questioning whether the scrutiny applied meets the standards ordinarily required for prescribing regulated compounds. The author argues that fundamental questions about molecular identity, dosing, and clinical basis are being bypassed in the committee's approach. The piece raises important concerns for prescribing clinicians navigating the evolving regulatory landscape around peptide therapeutics.

MedPage TodayJuly 29, 2026
4 min read
RegulatoryCritical

FDA offers updated guidance for generics of weight loss blockbusters

The FDA has issued revised draft guidance for generic drug developers seeking to create copycat versions of leading GLP-1 and GIP receptor agonist therapies, including semaglutide and tirzepatide. The updated guidance addresses bioequivalence and formulation standards that generic manufacturers must meet, signaling a significant regulatory step toward broader market competition for these blockbuster compounds. This development carries direct implications for compounding pharmacies and the broader GLP-1 prescribing landscape.

SemaglutideTirzepatideGLP-1GIP
Endpoints NewsJuly 28, 2026
4 min read
Clinical TrialsHigh

Thyroid Meds Recalled Nationwide; Worst GLP-1 for Hair Loss? PMOS Prevalence

A roundup covering multiple unrelated medical stories includes a report on the investigational triple agonist retatrutide, which met clinical endpoints in recent trial data. Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, representing a next-generation approach to metabolic disease treatment. The item on GLP-1 therapy and hair loss also surfaces as a patient-facing concern gaining attention in clinical practice.

RetatrutideGLP-1
MedPage TodayJuly 28, 2026
4 min read
Clinical TrialsHigh

Updated: Altimmune's GLP-1-based shot cuts drinking in patients with alcoholism

Altimmune announced positive Phase 2 results from its RECLAIM trial, demonstrating that pemvidutide, a GLP-1 and glucagon receptor dual agonist administered weekly, significantly reduced alcohol consumption in patients with moderate-to-severe alcohol use disorder. The findings expand the therapeutic potential of GLP-1 class peptides beyond metabolic and weight management indications into behavioral and addiction medicine. This trial adds to a growing body of evidence suggesting that GLP-1 receptor agonists may influence reward pathways associated with substance use.

PemvidutideGLP-1
Endpoints NewsJuly 28, 2026
4 min read
RegulatoryCritical

The future of gray-market peptides

An FDA advisory committee convened a two-day review to deliberate whether compounding pharmacies should retain the ability to produce seven specific peptides, a decision with sweeping implications for the compounding industry and patient access. The debate highlights ongoing regulatory tension between pharmaceutical manufacturers and compounding pharmacies over the legal status of peptide compounds. The outcome of this advisory process is expected to shape the future availability of widely used compounded peptide therapies.

BPC-157TB-500SermorelinIpamorelinCJC-1295PT-141Selank
Endpoints NewsJuly 28, 2026
5 min read
RegulatoryHigh

Montana's Right-to-Try Law Enters a New Phase

Montana has established its first experimental treatment review board, bringing prominent longevity researchers into the state's expanding framework for accessing unapproved therapies. The development marks a significant evolution in right-to-try legislation, raising important questions about the appropriate level of regulatory oversight for experimental peptide and longevity treatments. The initiative could serve as a model for other states seeking to broaden patient access outside of traditional FDA approval pathways.

Lifespan.ioJuly 28, 2026
4 min read
RegulatoryHigh

1,300 Dead in Outbreak; Cyclospora Response 'Mismanaged'? GLP-1 Access in Medicaid

A recent MedPage Today news roundup highlights ongoing policy discussions surrounding GLP-1 receptor agonist access within Medicaid programs, an issue with significant implications for patient equity and healthcare coverage. The inclusion of GLP-1 access as a key policy item underscores the expanding role these therapies play in public health debates at the state and federal level. Expanded Medicaid coverage for GLP-1 medications could affect millions of eligible patients managing obesity and metabolic conditions.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 27, 2026
3 min read
RegulatoryHigh

What Is the 'Barbie Peptide' and Why Is It Risky?

MedPage Today examines the growing social media trend surrounding an unregulated injectable peptide commonly referred to as the 'Barbie Peptide,' raising significant concerns among healthcare professionals about safety and consumer misuse. The peptide, promoted widely across social platforms, lacks regulatory approval and clinical validation for the cosmetic and wellness claims being made. Medical experts are calling attention to the risks of unsupervised self-administration and the broader challenge of policing peptide marketing in the digital age.

Melanotan II
MedPage TodayJuly 27, 2026
4 min read
RegulatoryHigh

STAT+: Pharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and more

An FDA advisory panel recommended that compounding pharmacies be permitted to produce two additional peptides, advancing a broader policy objective to improve patient access to peptide therapies. The recommendation aligns with ongoing efforts by health officials to expand the scope of compounds available through compounding channels. This development represents a noteworthy step in the evolving regulatory landscape governing compounded peptides.

STAT NewsJuly 27, 2026
4 min read
RegulatoryCritical

Six wellness peptides win backing from FDA advisory committee

An FDA advisory committee voted to lift restrictions on six popular health and wellness peptides following two days of meetings, overriding staff concerns about insufficient safety and efficacy data. The decision marks a significant regulatory shift that could expand access to compounded peptide therapies across the United States. The vote signals growing momentum within federal advisory bodies to reconsider existing limitations on peptide availability.

Endpoints NewsJuly 27, 2026
5 min read
ResearchMedium

More Autophagy Reduces Toxin-Induced Kidney Failure in Mice

New preclinical research demonstrates that enhancing autophagic flux can protect aging mice from acute kidney injury induced by toxic stress, a vulnerability not present in younger subjects. The findings highlight autophagy as a mechanistic target with potential therapeutic relevance, including for peptide-based compounds that modulate cellular repair and cytoprotective pathways. This research adds to the growing body of evidence supporting autophagy-enhancing strategies in age-related organ protection.

BPC-157
Lifespan.ioJuly 23, 2026
4 min read
LongevityMedium

Fight Aging! Newsletter, July 27th 2026

The Fight Aging! newsletter covers developments in longevity science and aging research, including topics relevant to cellular maintenance mechanisms and age-related disease intervention. This edition addresses neuromuscular junction function, immune system aging, and bone tissue maintenance, areas of ongoing interest within the peptide therapy and longevity research communities. Researchers and clinicians tracking peptide-based interventions for aging may find the discussed mechanisms relevant to emerging therapeutic targets.

Fight AgingJuly 26, 2026
5 min read